Duodenal Ulcer Treatment Market Report 2026

The duodenal ulcer treatment market size has grown strongly in recent years. It will grow from $107.34 billion in 2025 to $115.16 billion in 2026 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to acid suppression drug adoption, h pylori discovery, gastrointestinal disease burden, endoscopy availability, antibiotic therapy standardization.

The duodenal ulcer treatment market size is expected to see strong growth in the next few years. It will grow to $151.77 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to antibiotic resistance management, novel acid blockers, early diagnosis programs, outpatient ulcer management, personalized gastroenterology care. Major trends in the forecast period include increasing use of combination drug therapy, rising focus on helicobacter pylori eradication, expansion of proton pump inhibitor usage, growth of minimally invasive surgical interventions, improved patient compliance through simplified regimens.

The rising number of cigarette smokers is expected to drive the growth of the duodenal ulcer treatment market in the coming years. Cigarette smokers are individuals who regularly consume tobacco-containing cigarettes, inhaling the smoke produced by combustion. Smoking rates are increasing due to cultural influences, socioeconomic factors, stress-related behaviors, and greater access to nicotine products. The duodenal ulcer treatment market supports this trend by offering ulcer-specific therapies, smoking-cessation programs, lifestyle guidance, and ongoing monitoring to promote healing and reduce recurrence. For instance, in October 2024, according to the European Respiratory Society (ERS), a Switzerland-based non-profit organization, a study on smoking trends among young people showed a significant rise in smoking rates, with 22.5% of respondents smoking in 2022 compared to 40.1% in 2024. Therefore, the increase in cigarette smokers is driving the growth of the duodenal ulcer treatment market.

Major companies in the duodenal ulcer treatment market are focusing on developing innovative products such as combikits for duodenal ulcers associated with Helicobacter pylori (H. pylori) infection to improve treatment outcomes and healing effectiveness. A combikit for duodenal ulcer and H. pylori infection is a combination therapy pack containing multiple medications designed to eradicate H. pylori bacteria while reducing gastric acid production, addressing both the underlying cause and symptoms of duodenal ulcers. For example, in April 2023, Akums Drugs and Pharmaceutical Limited, an India-based pharmaceutical company, launched an innovative Combikit for treating duodenal ulcers associated with H. pylori infection. The kit includes amoxicillin, clarithromycin, and esomeprazole, which work together to inhibit bacterial growth and decrease gastric acid secretion. Approved by the Central Drugs Standard Control Organization (CDSCO), this Combikit provides an integrated and effective approach to treat duodenal ulcers and eradicate H. pylori in patients with active or healed peptic ulcers.

In July 2024, Zydus Lifesciences Limited, an India-based pharmaceutical company, partnered with Takeda Pharmaceutical Company to secure a non-exclusive patent licensing agreement for marketing Vonoprazan (Vault®) in India. This partnership aims to expand Zydus’s gastroenterology portfolio by introducing a next-generation acid-suppressing therapy in India and improving patient access to innovative treatments for acid-related disorders. Takeda Pharmaceutical Company, a Japan-based firm, specializes in treatments for duodenal ulcers.

Major companies operating in the duodenal ulcer treatment market are Pfizer Inc., Merck & Co. Inc., Bayer AG, Sanofi S.A, Bristol-Myers Squibb, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sandoz AG, Sun Pharmaceutical Industries Limited, Eisai Co. Ltd., Aurobindo Pharma Limited, Cipla Inc., Dr. Reddy's Laboratories Limited, Intas Pharmaceuticals Limited, Apotex Inc., Lupin Limited, Glenmark Pharmaceuticals Limited, Alkem Laboratories Limited, Jubilant Pharma Limited, Torrent Pharmaceuticals Limited.

North America was the largest region in the duodenal ulcer treatment market in 2025. The regions covered in the duodenal ulcer treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the duodenal ulcer treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the duodenal ulcer treatment market by increasing costs of imported antibiotics, proton pump inhibitors, diagnostic tools, and endoscopy equipment. Hospitals and gastroenterology clinics in developed regions are most affected. These tariffs raise treatment costs by increasing drug procurement and procedural expenses, affecting affordability and potentially delaying diagnosis and intervention. However, they promote domestic pharmaceutical manufacturing and localized diagnostic supply chains, strengthening regional production capabilities for ulcer therapies and medical equipment.

The duodenal ulcer treatment market research report is one of a series of new reports that provides duodenal ulcer treatment market statistics, including duodenal ulcer treatment industry global market size, regional shares, competitors with a duodenal ulcer treatment market share, detailed duodenal ulcer treatment market segments, market trends and opportunities, and any further data you may need to thrive in the duodenal ulcer treatment industry. This duodenal ulcer treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Duodenal ulcer treatment refers to the therapeutic strategies used to heal and manage ulcers in the duodenum, the first part of the small intestine. This approach typically combines medications to reduce acid production and promote healing, lifestyle modifications, and, in some cases, interventions to eliminate Helicobacter pylori bacteria, a common cause of duodenal ulcers.

The main types of duodenal ulcer treatment include antibiotics, proton pump inhibitors, antacids, potassium-competitive acid blockers, H2-antagonists, ulcer-protective drugs, and surgery. Antacids are medications used to treat bacterial infections, such as those caused by Helicobacter pylori, helping to eradicate the infection and allow the ulcer to heal. Treatments are applied to adults and elderly patients, and distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies.

The duodenal ulcer treatment market consists of revenues earned by entities by providing services such as endoscopic therapies, follow-up care, and lifestyle and dietary changes. The market value includes the value of related goods sold by the service provider or included within the service offering. The duodenal ulcer treatment market also includes sales of endoscopic devices, surgical instruments, H2-receptor antagonists, and diagnostic tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.